Caribou reports long-term data for vispa-cel in lymphoma patients
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026
June 11, 2026 8:01 AM EDT-- Single dose of vispa-cel produced durable responses in 2L LBCL patients: 82% ORR, 67% CR rate, and 17.1-month mPFS --
-- Generally well-tolerated safety profile continues to support outpatient administration and further expansion to community centers --
-- ANTLER-3 pivotal phase 3 trial designed to address the unmet need in 2L LBCL patients at academic and community centers who lack treatment options with curative intent --
-- EHA oral presentation scheduled for Friday, June 12, 2026, at 5:15pm CEST --
BERKELEY, Calif., June 11, 2026 (GLOBE NEWSWIRE) --... More
